The amyloid beta 42/38 ratio as a plasma biomarker of early memory deficits in cognitively unimpaired older adults
The amyloid beta (Aβ) 42/40 ratio has been widely studied as a biomarker in Alzheimer's disease (AD); however, other Aβ peptides could also represent relevant biomarkers. We measured levels of Aβ38/40/42 in plasma samples from cognitively-unimpaired older adults and determined the relationships between Aβ levels and amyloid positron-emission-tomography (PET) and performance on a learning and memory task. We found that all Aβ peptides individually and the Aβ42/40 ratio, but not the Aβ42/38 ratio, were significantly correlated with brain amyloid (Aβ-PET). Multiple linear modeling, adjusting for age, sex, education, APOE4 and Aβ-PET showed significant associations between the Aβ42/38 ratio and memory. Further, associations between the Aβ42/38 ratio and learning scores were stronger in males and in Aβ-PET-negative individuals. In contrast, no significant associations were detected between the Aβ42/40 ratio and any learning measure. These studies implicate the Aβ42/38 ratio as a biomarker to assess early memory deficits and underscore the utility of the Aβ38 fragment as an important biomarker in the AD field.
Authors
- Alison Bamford
- Rond Malhas (ORCID: https://orcid.org/0009-0003-6227-2079)
- Liv McMillan (ORCID: https://orcid.org/0000-0001-5077-7799)
- Elizabeth A. Thomas (ORCID: https://orcid.org/0000-0002-2024-4710)
- Jenna N. Adams (ORCID: https://orcid.org/0000-0002-6702-3851)
- Mark E. Mapstone (ORCID: https://orcid.org/0000-0003-0280-8057)
- Michael A. Yassa (ORCID: https://orcid.org/0000-0002-8635-1498)
- Brian D. Hitt (ORCID: https://orcid.org/0000-0001-8720-6762)
- Soyun Kim (ORCID: https://orcid.org/0000-0003-0165-2556)
Institutions
- University of California, Irvine (US)
- Bioscience Research (US)
Publication Details
- Journal
- Neurobiology of Aging
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1016/j.neurobiolaging.2024.08.009
- Citations
- 4
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.31
Funders
- Alzheimer's Drug Discovery Foundation
- National Institutes of Health